Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Planning and Dissemination Grant - Institute Community Support

McMaster University

$20,000.00

Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY) International Randomized Controlled Trial: Evidence Dissemination from a Large International Prospective Dataset

EF 2021-22

Résumé
Bone cancer in the leg is most commonly treated with extensive reconstructive operations with the goal of saving the leg and avoiding amputation. These complex operations are associated with a high risk of infection after surgery. Infections after surgery can be devastating for patients because they frequently require long-term intravenous antibiotics, multiple operations, and often result in eventual amputation. The identification of the best preventative antibiotic regimen was established as the primary research priority in the field of musculoskeletal cancer surgery by the Musculoskeletal Tumor Society, the leading North American society in the field. With CIHR funding (Spring 2014 Project Grant Funding Competition), we conducted the Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY) trial to address this research priority. Surgeons from 48 hospitals across 12 countries and 6 continents randomly allocated 611 patients to receive either one- or five-days of intravenous antibiotics after surgery between January 2013 and October 2019. Ultimately, the results of this study suggest that prolonging the use of antibiotics beyond one day after surgery does not reduce the rate of infection but does significantly increase the risk of having a serious antibiotic-related complication. More importantly, the PARITY trial dataset is the largest prospectively collected dataset in the field of musculoskeletal cancer surgery. We aim to use our dataset to address other unanswered clinical questions in the field. However, due to the across-the-board 30% budget cuts during the Spring 2014 CIHR funding competition, we had to limit our dissemination initiatives. At present, we are requesting further funding to complete our dissemination activities as originally planned.
Programme
Planning and Dissemination Grant - Institute Community Support
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
460959
Name
Ghert Michelle A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Clinical
Prcname2
Planning and Dissemination - IMHA
Projecttitle
Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY) International Randomized Controlled Trial: Evidence Dissemination from a Large International Prospective Dataset
Programtype2
Miscellaneous Programs
Orgnameinp2
McMaster University
Cihramount2
$20,000
Cihrequipment2
$0
Programname2
Planning and Dissemination Grant - Institute Community Support
Keyworddelim
Antibiotics; Dissemination; Knowledge Translation; Musculoskeletal Oncology; Randomized Controlled Trial; Sarcoma; Sarcoma Surgery; Surgical Site Infection
Abstract
Bone cancer in the leg is most commonly treated with extensive reconstructive operations with the goal of saving the leg and avoiding amputation. These complex operations are associated with a high risk of infection after surgery. Infections after surgery can be devastating for patients because they frequently require long-term intravenous antibiotics, multiple operations, and often result in eventual amputation. The identification of the best preventative antibiotic regimen was established as the primary research priority in the field of musculoskeletal cancer surgery by the Musculoskeletal Tumor Society, the leading North American society in the field. With CIHR funding (Spring 2014 Project Grant Funding Competition), we conducted the Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY) trial to address this research priority. Surgeons from 48 hospitals across 12 countries and 6 continents randomly allocated 611 patients to receive either one- or five-days of intravenous antibiotics after surgery between January 2013 and October 2019. Ultimately, the results of this study suggest that prolonging the use of antibiotics beyond one day after surgery does not reduce the rate of infection but does significantly increase the risk of having a serious antibiotic-related complication. More importantly, the PARITY trial dataset is the largest prospectively collected dataset in the field of musculoskeletal cancer surgery. We aim to use our dataset to address other unanswered clinical questions in the field. However, due to the across-the-board 30% budget cuts during the Spring 2014 CIHR funding competition, we had to limit our dissemination initiatives. At present, we are requesting further funding to complete our dissemination activities as originally planned.
Competitiondate
202202
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ghert, Michelle A
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Musculoskel Hlth &Arth~ $20,000~ $0~